|

Olverembatinib Clinical Trials

9 actively recruiting trials across 1 location

Also known as: 6-MP, Cytarabine, Daunorubicin, Dexamethasone, Methotrexate +5 more

Pipeline

Phase 2: 3Phase 3: 3Phase 1/2: 1

Top Sponsors

  • Ascentage Pharma Group Inc.3
  • Institute of Hematology & Blood Diseases Hospital, China2
  • The First Affiliated Hospital of Soochow University1
  • Peking University People's Hospital1
  • M.D. Anderson Cancer Center1

Indications

  • Cancer9
  • Chronic Myeloid Leukemia3
  • Relapsed/Refractory Acute Myeloid Leukaemia1
  • Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)1
  • Childhood Leukemia, Acute Lymphoblastic1

Other7 trials

A Study of Olverembatinib in SDH-deficient GIST.
Phase 3
Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL
N/A
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
Phase 3
Olverembatinib for FGFR1-rearranged Neoplasms
Phase 2
Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Phase 1/2
The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP
Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
Phase 2

Houston, Texas2 trials

Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

MD Anderson Cancer Center

Phase 2
Study of Olverembatinib (HQP1351) in Patients With CP-CML

MD Anderson Cancer Center

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.